Literature DB >> 16996986

Repair of the damaged heart by bone marrow cells: from experimental evidence to clinical hope.

Keng-Leong Ang1, Lincoln Takura Shenje, Lakshmi Srinivasan, Manuel Galiñanes.   

Abstract

Heart failure remains the leading cause of death in developed countries in spite of improvements in medical and surgical treatments. However, recent observations in experimental studies that bone marrow cells may repair cardiac tissue have offered renewed hopes for the treatment of heart failure. This optimism is further supported by encouraging results from some clinical trials, although the degree of benefits, the underlying mechanisms, and the cell types involved remain to be elucidated. This review summarizes the relevant experimental and clinical studies supporting the use of bone marrow cells in myocardial repair, as well as the controversies and challenges encountered.

Entities:  

Mesh:

Year:  2006        PMID: 16996986     DOI: 10.1016/j.athoracsur.2006.05.047

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

Review 1.  "AKT"ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation.

Authors:  Mark Sussman
Journal:  Trends Cardiovasc Med       Date:  2007-10       Impact factor: 6.677

2.  Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure.

Authors:  Philippe Menasché
Journal:  J Cardiovasc Transl Res       Date:  2008-03-14       Impact factor: 4.132

Review 3.  Cell-based therapy for heart disease: a clinically oriented perspective.

Authors:  Philippe Menasche
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

4.  Intramyocardial implantation of autologous bone marrow-derived stem cells combined with coronary artery bypass grafting in patients with ischemic cardiomyopathy: a pilot study.

Authors:  P Antonitsis; K Anastasiadis; G Koliakos; C Vaitsopoulou; K Kouzi-Koliakou; A Doumas; H Argiriadou; P Tossios
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.